Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story
Α
A Growing high-value Biosimilars contribution
Net sales by business
2023 2028 (illustrative)
=
-20%
-80%
Mid-single digit growth¹
2023
Generics
Biosimilars
Generics
Biosimilars
-30%
~70%
2028
1. In constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31;
2. LoE value covered based on Company analysis using Sandoz IP and IP database.
19
Management Presentation
Broad growth in Generics
Attractive pipeline of >400
products targeting USD 145bn
of Originator sales²
Well-positioned to leverage
strong Biosimilars pipeline
25 molecules in the pipeline
Four key Biosimilars launches
of Adalimumab HCF,
Natalizumab, Denosumab and
Aflibercept
SANDOZView entire presentation